Should preserving contract pharmacy arrangements be a policy priority when the evidence shows that many of these arrangements benefit large pharmacy chains and intermediaries as much—or more—than the patients Congress ultimately intended to help with 340B has created over 30 years ago?
Related Posts
Legislators object to proposed CMS payment changes for diabetes tech
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: The co-chairs of the House […]
How Trump’s megabill will impact health care
The massive tax cut legislation passed by the House and Senate this week will dramatically upend health care in America. The legislation, now on its […]
Sectra Acquires Oxipit to Scale Autonomous Diagnostic Imaging
What You Should Know The Deal: Swedish medical imaging and cybersecurity giant Sectra has entered into an agreement to acquire Oxipit, a Lithuanian startup specializing […]